Search  in | Advanced
   Print  

Plenary Session
The Crown Jewels Of Scientific Abstracts

Among the 626 scientific oral and poster abstracts accepted for presentation in Anaheim, six “gems” were selected for the plenary session. Be sure to make time in your Annual Meeting schedule to hear these outstanding presentations, Monday from 8:30 to 10:00 am in Room 204B.

  • The Canadian Transfusion Error Surveillance System (TESS): Results from the First Two Years of a National Pilot Project, Jeannie L. Callum, MD, presenting. This study analyzed data from 11 hospitals in four provinces to determine rates for several errors, including ABO-incompatible transfusions, inappropriate transfusions, product wastage, the need for sample re-collection and treatment delays. Data were stratified for hospital size, personnel involved and points in the “transfusion chain” where errors occurred.

  • U.S. Blood Donor Screening for Trypanosoma cruzi: Clinical Studies and Early Assessment of Prevalence, Susan L. Stramer, PhD, presenting. In support of test licensure, a prevalence study was initiated under an investigational new drug protocol. The study involved areas where T. cruzi-infected donors had already been identified. Donors with reactive and nonreactive gray zone test results were asked to participate in follow-up studies that included additional laboratory assays as well as a donor risk survey.

  • Evaluation of Proposed FDA Criteria for Radiolabeled Red Cell Recovery Trials, Larry J. Dumont, MBA, PhD, presenting for the Biomedical Excellence for Safer Transfusion (BEST) Collaborative. The objective of this study was to define the ability of systems for red cell collection and storage to meet the criteria set by the FDA for recovery of autologous red cells 24 hours after reinfusion. Those criteria call for a mean recovery of 75%, a standard deviation of 9%, and a greater than 75% rate of success for individual recovery.

  • Relationship of HLA Antibodies in Blood Donors to Pregnancy and Transfusion History, Darrell J. Triulzi, MD, presenting. For this study, six blood centers recruited approximately 7,900 blood donors and asked for a detailed history of pregnancy and/or transfusion, as well as a blood sample for leukocyte antibody testing. The aim was to determine the percentage of donors whose plasma-rich components would be diverted in an effort to reduce the risk of transfusion-related acute lung injury.

  • Ex-Vivo Production of Human Red Blood Cells by Coculture with Human Mesenchymal Stem Cells, Eun-Jung Baek, MD, PhD, presenting. This study compared the differentiation of CD34+ cells into erythroid lineage and massive production of red cells by coculture with either marrow-derived or cord blood mesenchymal stem cells. The protocols involved supplementation with stem cell factor, interleukin 3, erythropoietin, thrombopoietin, Flt-3 ligand, or absence of any cytokines.

  • Complications of Whole Blood Donation in 16- and 17-Year-Old Allogeneic Donors, Anne F. Eder, MD, PhD, presenting. The goal of this study was to evaluate the safety of allowing 16-year-old high school students to donate blood with parental consent. Complications analyzed included prefaint reactions, loss of consciousness (with and without injury), hematoma, prolonged recovery, and receipt of outside medical care.


Abstracts at a Glance

Category               2007       2006       2005       2004       2003       2002     2001       

Submitted

     Domestic         570         545         521         533         457         465         405        

     International    307         250         281         226         230         172         246        

     Total                  877         795         802         759         687         637         651        

Accepted

     Domestic         536         506         472         458         400         386         404        

     International    278         217         242         192         184         130         247        

     Total                  814         723         714         650         584         516         531        

Acceptance Rate (%)

     Domestic           94           93           91           86           88           83           99        

     International      90           87           86           85           85           76           99

Scientific

     Oral                   114         105         102         108         142         100         150        

     Poster               512         398         424         382         302         309         294        

     Total                  626         503         526         490         444         409         444        

Administrative

     Oral                     24           24           24           12             8              9              6

     Poster               158         189         158         152         132           90           74

     Total                  182         213         182         164         140           99           80

 

Note: Totals of scientific and administrative abstracts do not equal total

accepted because some presenters withdraw after acceptance.



 Back to Saturday

Last modified on 10/19/2007 2:33:01 PM
What's New!
AABB Weekly Report - August 15, 2008
Details
Summary of Draft Comments to be Submitted to TJC on Blood Management Performance Measures
Details
Significant Changes to the Standards for Cellular Therapy Product Services, 3rd edition
Details
Proposed 6th edition of Standards for Immunohematology Reference Laboratories
Details
First Ever National Biovigilance Network in the U.S. Reaches $1 Million in Funding, Prepares for Fall Pilot Launch
Details
Billing and Reimbursement for Stem Cell Processing - Frequently Asked Questions and Answers
Details
2008 West Nile Virus Biovigilance Network
Details
List of AABB-Accredited Facilities with Approved Variances for ISBT 128
Details
Instructions on Applying for an AABB Variance
Details